Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.

The IMPULS trial is a randomized, triple-blinded, placebo controlled, single center, pilot trial examining the efficacy and safety of preoperative propranolol in patients scheduled for pancreatic cancer surgery. The study is conducted as a type 1 hybrid efficacy-implementation trial of 30 patients. This study is designed to provide pilot data for a future larger perioperative study of propranolol with the aim of improving outcomes for pancreatic cancer surgery. In total, 30 participants will be allocated in a 1:1 ratio with 15 participants enrolled in each trial arm (propranolol vs. placebo)

Trial Details

NCT ID
NCT06145074
Phase
PHASE2
Sponsor
Zealand University Hospital
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • Propranolol
  • Placebo
Locations (sample)
  • Copenhagen, Denmark|55.67594,12.56553
  • Køge, Denmark|55.45802,12.18214

Key Eligibility Criteria

  • Patients with suspected surgically resectable pancreatic cancer
  • Indication for surgical treatment with curative intend.
  • Provide written informed consent.
  • Patients minimum 18 years old.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →